Outcome assessments in rheumatoid arthritis

Katarzyna Gilek-Seibert, Kara Prescott, Salahuddin Kazi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Increasing evidence suggests low disease activity or remission is achievable in rheumatoid arthritis (RA). Using a treat to target strategy (T2T) has been shown to achieve these targets of remission or low disease activity in RA. In order to successfully treat to target, rheumatologists need reliable measures of disease activity to switch and/or escalate therapy to achieve or maintain therapeutic targets. Multiple diseaseactivity measures have been developed for both research and clinical practice. For clinical practice, the American College of Rheumatology (ACR) has recommended the PAS, PAS II, RAPID 3, CDAI, DAS 28, and SDAI for measuring disease activity in rheumatoid arthritis. Each of these measures has strengths and limitations, but they all accurately reflect disease activity, discriminate well between disease states, and are feasible to perform in the clinical setting. Implementation in the clinical setting can be optimized through leveraging technology and systems redesign. Tools such as web-based and smartphone applications have been developed to increase the ease with which these measures can be deployed. Diseaseactivity measurement in rheumatoid arthritis is included in the rheumatoid arthritis quality measures group in the Centers for Medicare and Medicaid Services' incentive-based Physician Quality Reporting System.

Original languageEnglish (US)
Article number370
JournalCurrent Rheumatology Reports
Volume15
Issue number11
DOIs
StatePublished - Nov 2013

Fingerprint

Rheumatoid Arthritis
Outcome Assessment (Health Care)
amsonic acid
Centers for Medicare and Medicaid Services (U.S.)
Motivation
Technology
Physicians
Therapeutics
Research

Keywords

  • ACR
  • American College of Rheumatology
  • CDAI
  • DAS
  • DAS 28
  • Disease activity measures
  • EULAR
  • European league against Rheumatism
  • Guidelines
  • Medical apps
  • Outcomes
  • PAS
  • PAS II
  • Patient-reported outcomes
  • RAPID3
  • Rheumatoid arthritis (RA)
  • SDAI
  • Treat to target strategy

ASJC Scopus subject areas

  • Rheumatology
  • Medicine(all)

Cite this

Outcome assessments in rheumatoid arthritis. / Gilek-Seibert, Katarzyna; Prescott, Kara; Kazi, Salahuddin.

In: Current Rheumatology Reports, Vol. 15, No. 11, 370, 11.2013.

Research output: Contribution to journalArticle

@article{a25618dabb4a42cda3f46f5af763777c,
title = "Outcome assessments in rheumatoid arthritis",
abstract = "Increasing evidence suggests low disease activity or remission is achievable in rheumatoid arthritis (RA). Using a treat to target strategy (T2T) has been shown to achieve these targets of remission or low disease activity in RA. In order to successfully treat to target, rheumatologists need reliable measures of disease activity to switch and/or escalate therapy to achieve or maintain therapeutic targets. Multiple diseaseactivity measures have been developed for both research and clinical practice. For clinical practice, the American College of Rheumatology (ACR) has recommended the PAS, PAS II, RAPID 3, CDAI, DAS 28, and SDAI for measuring disease activity in rheumatoid arthritis. Each of these measures has strengths and limitations, but they all accurately reflect disease activity, discriminate well between disease states, and are feasible to perform in the clinical setting. Implementation in the clinical setting can be optimized through leveraging technology and systems redesign. Tools such as web-based and smartphone applications have been developed to increase the ease with which these measures can be deployed. Diseaseactivity measurement in rheumatoid arthritis is included in the rheumatoid arthritis quality measures group in the Centers for Medicare and Medicaid Services' incentive-based Physician Quality Reporting System.",
keywords = "ACR, American College of Rheumatology, CDAI, DAS, DAS 28, Disease activity measures, EULAR, European league against Rheumatism, Guidelines, Medical apps, Outcomes, PAS, PAS II, Patient-reported outcomes, RAPID3, Rheumatoid arthritis (RA), SDAI, Treat to target strategy",
author = "Katarzyna Gilek-Seibert and Kara Prescott and Salahuddin Kazi",
year = "2013",
month = "11",
doi = "10.1007/s11926-013-0370-y",
language = "English (US)",
volume = "15",
journal = "Current Rheumatology Reports",
issn = "1523-3774",
publisher = "Current Science, Inc.",
number = "11",

}

TY - JOUR

T1 - Outcome assessments in rheumatoid arthritis

AU - Gilek-Seibert, Katarzyna

AU - Prescott, Kara

AU - Kazi, Salahuddin

PY - 2013/11

Y1 - 2013/11

N2 - Increasing evidence suggests low disease activity or remission is achievable in rheumatoid arthritis (RA). Using a treat to target strategy (T2T) has been shown to achieve these targets of remission or low disease activity in RA. In order to successfully treat to target, rheumatologists need reliable measures of disease activity to switch and/or escalate therapy to achieve or maintain therapeutic targets. Multiple diseaseactivity measures have been developed for both research and clinical practice. For clinical practice, the American College of Rheumatology (ACR) has recommended the PAS, PAS II, RAPID 3, CDAI, DAS 28, and SDAI for measuring disease activity in rheumatoid arthritis. Each of these measures has strengths and limitations, but they all accurately reflect disease activity, discriminate well between disease states, and are feasible to perform in the clinical setting. Implementation in the clinical setting can be optimized through leveraging technology and systems redesign. Tools such as web-based and smartphone applications have been developed to increase the ease with which these measures can be deployed. Diseaseactivity measurement in rheumatoid arthritis is included in the rheumatoid arthritis quality measures group in the Centers for Medicare and Medicaid Services' incentive-based Physician Quality Reporting System.

AB - Increasing evidence suggests low disease activity or remission is achievable in rheumatoid arthritis (RA). Using a treat to target strategy (T2T) has been shown to achieve these targets of remission or low disease activity in RA. In order to successfully treat to target, rheumatologists need reliable measures of disease activity to switch and/or escalate therapy to achieve or maintain therapeutic targets. Multiple diseaseactivity measures have been developed for both research and clinical practice. For clinical practice, the American College of Rheumatology (ACR) has recommended the PAS, PAS II, RAPID 3, CDAI, DAS 28, and SDAI for measuring disease activity in rheumatoid arthritis. Each of these measures has strengths and limitations, but they all accurately reflect disease activity, discriminate well between disease states, and are feasible to perform in the clinical setting. Implementation in the clinical setting can be optimized through leveraging technology and systems redesign. Tools such as web-based and smartphone applications have been developed to increase the ease with which these measures can be deployed. Diseaseactivity measurement in rheumatoid arthritis is included in the rheumatoid arthritis quality measures group in the Centers for Medicare and Medicaid Services' incentive-based Physician Quality Reporting System.

KW - ACR

KW - American College of Rheumatology

KW - CDAI

KW - DAS

KW - DAS 28

KW - Disease activity measures

KW - EULAR

KW - European league against Rheumatism

KW - Guidelines

KW - Medical apps

KW - Outcomes

KW - PAS

KW - PAS II

KW - Patient-reported outcomes

KW - RAPID3

KW - Rheumatoid arthritis (RA)

KW - SDAI

KW - Treat to target strategy

UR - http://www.scopus.com/inward/record.url?scp=84893814230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893814230&partnerID=8YFLogxK

U2 - 10.1007/s11926-013-0370-y

DO - 10.1007/s11926-013-0370-y

M3 - Article

C2 - 24072601

AN - SCOPUS:84893814230

VL - 15

JO - Current Rheumatology Reports

JF - Current Rheumatology Reports

SN - 1523-3774

IS - 11

M1 - 370

ER -